Company continues to supply high-quality medicines to approximately 1 billion patients annually Report chronicles Viatris' commitment to providing access to healthcare and building healthier communities Impactful story highlights include "Empathy in Africa: Bridging the Healthcare Divide" – a powerful new documentary short that showcases Viatris' impact PITTSBURGH, May 21, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2023 Sustainability Report: Building ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpora ...

Viatris Inc. (VTRS) delivered adjusted earnings of 67 cents per share in the first quarter of 2024, missing the Zacks Consensus Estimate by a penny. The company recorded adjusted earnings of 77 cents in the year-ago quarter.Total revenues came in at $3.66 billion, down 1.7% year over year. Revenues include product sales and other revenues. The top line missed the Zacks Consensus Estimate of $3.7 million.Viatris’ stock is trading down in response to the first-quarter results mainly due to a miss on both earn ...

Viatris Inc. (NASDAQ:VTRS) Q1 2024 Earnings Call Transcript May 9, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Conference Call Participants Nathan Rich - Goldman Sachs Bhavin Patel - Bank of America Glen Santangelo - Jefferies Ash Verma - UBS Chris Schott - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning and welcome to Viatris Q1 2024 Earnings Conference Call. ...

For the quarter ended March 2024, Viatris (VTRS) reported revenue of $3.66 billion, down 1.8% over the same period last year. EPS came in at $0.67, compared to $0.78 in the year-ago quarter. The reported revenue represents a surprise of -2.12% over the Zacks Consensus Estimate of $3.74 billion. With the consensus EPS estimate being $0.68, the EPS surprise was -1.47%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Viatris (VTRS) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.47%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.67 per share when it actually produced earnings of $0.61, delivering a surprise of -8.96%.Over the last four quarters, the compan ...

Lara Ramsburg Chief Corporate Affairs Officer Brian Roman Chief Legal Officer Q1 2024 Select Key Product Net Sales, on a Consolidated Basis 22 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2024 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Full-Year 2024 Guidance Items as of May 9, 2024(1) | --- | --- | |--------------------- ...

• Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million; and Free Cash Flow of $565 Million for the First Quarter • Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1] • Reaffirms 2024 New Product Revenue Range of $450 Million to $550 Million • Closes Idorsia Transaction, Expanding Por ...

Investors are always looking for stocks that are poised to beat at earnings season and Viatris Inc. (VTRS) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Viatris is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicato ...

Viatris (VTRS) , a global healthcare company, is scheduled to report first-quarter results on May 9, 2024.The company’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.78%. In the last reported quarter, the company missed on earnings by 8.96%.Factors to ConsiderViatris reports revenues under two divisions in terms of product category —brands and generics.Brand business makes up about two-thirds of the company’s portfolio. This category is ...